Status:
COMPLETED
Pain in Autism Spectrum Disorder
Lead Sponsor:
Rambam Health Care Campus
Conditions:
High-functioning Autism
Eligibility:
All Genders
18-45 years
Brief Summary
The proposed project will be first performed on individuals with HF-ASD with their expected heterogeneity and healthy control (HC) subjects in order to explore the pain processing and modulation mecha...
Detailed Description
A dysregulation of the balance between excitatory and inhibitory neural activity (i.e. an E/I imbalance) underlies ASD pathology. Neural hyper-responsiveness and impaired top-down modulation represent...
Eligibility Criteria
Inclusion
- Proficiency in using the Hebrew language;
- Verbal performance and full scale estimate of 80 and above on the WASI
- No use of pain medication for the past 24 hours.
- Inclusion criteria for the ASD group: A diagnosis of HF-ASD based on the ADOS-2
Exclusion
- 1\) Diagnosis of chronic pain.
Key Trial Info
Start Date :
May 6 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 17 2022
Estimated Enrollment :
183 Patients enrolled
Trial Details
Trial ID
NCT03413241
Start Date
May 6 2018
End Date
February 17 2022
Last Update
April 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The lab of clinical neurophysiology, the faculty of medicine, Technion and Rambam Medical Center
Haifa, Israel